This site is intended for healthcare professionals
News

Farxiga DAPA-CKD Phase III trial reduced worsening of kidney function, risk of cardiovascular or renal death in patients with chronic kidney disease, irrespective of underlying cause.- AstraZeneca

Read time: 1 mins
Last updated:27th Oct 2020
Published:24th Oct 2020
A new subgroup analysis from the ground-breaking DAPA-CKD Phase III trial showed that AstraZeneca’s Farxiga (dapagliflozin), on top of standard of care, reduced the composite of worsening of kidney function or risk of cardiovascular (CV) or renal death in patients with chronic kidney disease (CKD), irrespective of the underlying cause of the disease.
Condition: Diabetes Type 2 and Kidney Disease
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest